Penumbra manufactures several medical devices but specializes in the neuro/vascular market and creates devices that help treat aneurysms and ischemic
stroke.[7][8]
In 2014, Penumbra launched its Apollo system, a device that “enables minimally invasive removal of deeply seated tissue and fluids in the brain,” allowing for otherwise inoperable blood clots to be removed.[9][10]
In 2015 the company issued an IPO on the
NYSE.[11] In 2018 the company acquired 40% of the outstanding shares of virtual reality joint venture MVI Health.[12] In 2017 the company acquired the Italian distributor
Crossmed.[13]
Criticism
Criticism of Penumbra has followed various aspects of its products and business practices. In 2016 a lawsuit claimed the Penumbra Coil 400 caused brain damage after surgery.[14] The company's specialized catheter has been linked to the deaths of stroke patients, and it was a target of stock short sellers in 2020.[15][16][17][excessive citations] According to the Foundation for Financial Journalism, this is a significant dilemma.[18]
A request has been sent to The SEC and U.S. Food and Drug Administration to launch an investigation.[19] A scientist who has published research articles showing the reliability of Penumbra's medical products is (allegedly) an internet fabrication.[20]
Recalls
In 2011 the company recalled its Penumbra Coil 400.[21] In 2017 the company recalled a 3D revascularization device.[22] In 2020 the company recalled one of its catheter used during heart surgery due to increased risk of mortality and serious injury.[23][24][25][excessive citations]